

"GENETIC BASIS OF RARE DISEASES: ADVANCES IN DIAGNOSIS AND THERAPEUTIC APPROACHES"

Dr. Muhammad Amjad Chisti¹, Maryam Jan², Imran Hussain³, Abdul Basit^{*4}, Atif Rasool⁵

¹Department of Eastern Medicine, Superior University Lahore

²Cholistan University of Veterinary and Animal Sciences Bahawalpur

³Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur,

^{*4}Department of Eastern Medicine, faculty of Medicine and Allied Health Sciences, The Islamia University of Bahawalpur

⁵Punjab University College of Pharmacy Lahore

¹muhammadamjadchishti@gmail.com, ²jan461455@gmail.com, ³jamimranhussain1996@gmail.com, ^{*4}abdulbasit81402@gmail.com, ⁵atifrasool395@gmail.com

DOI: <https://doi.org/10.5281/zenodo.15308807>

Keywords

Article History

Received on 23 March 2025

Accepted on 23 April 2025

Published on 30 April 2025

Copyright @Author

Corresponding Author: *

Abdul Basit

Department of eastern medicine,
faculty of medicine and Allied
health sciences, The Islamia
university of Bahawalpur
abdulbasit81402@gmail.com

Abstract

Mutation disabilities are behind rare diseases that cause heavy barriers to diagnosis and therapy. The study deals with rare disease genetics through diverse molecular techniques, which include mutation screening based on PCR, NGS, CMA, gene expression profiling, and CRISPR-Cas9 Gene editing, etc. Genomic DNA of good quality was extracted from the patient's samples and targeted sequencing has identified multiple pathogenic mutations. Whole-exome sequencing (WES) in combination with CMA has brought about the identification of some novel single nucleotide polymorphisms (SNPs), copy number variations (CNVs), as well as structural rearrangements, some of which are without previous reports. Analysis of gene expression has shown considerable dysregulation across major genes associated with the disease, with effective validation by Western blot matching alteration with protein levels. Functional validation by CRISPR-Cas9 was successful in restoring both normal gene and protein functions by correcting pathogenic mutations, careful statistical analysis presents a strong association of genetic alterations with disease phenotypes that confirm the clinical importance of these mutations identified. This study stresses the blend of multiple techniques for molecular diagnosis and treatment advancement even though variants may still be labeled uncertain. Findings pave the way for targeted gene therapies for rare diseases, thereby advancing the field of precision medicine. Future efforts should concentrate on widening patient cohorts and new treatment paradigms to improve treatment outcomes for individuals suffering from genetic diseases. This study stresses the knowledge of genetic pathophysiology and its application to personalized medicine.

INTRODUCTION

Rare diseases, often referred to as orphan diseases, represent a diverse group of disorders that affect a

small percentage of the population. According to the World Health Organization (WHO), the disease is

classified as rare when it affects fewer than one in 2,000 individuals[1, 2]. On the other hand, although the rare disease is of low importance on an individual basis, they represents diseases that collectively disturb millions of people across the globe. Most of these disorders are genetically determined; they stem from mutations of one or more single genes, chromosomal abnormalities, or complex interplay of several environmental or genetic factors. Advances over the last decades in genetic research have opened avenues that have revolutionized the comprehension of such disorders from early diagnosis to targeted therapeutic intervention[3].

Genetic disorders are extremely rare: extremely rare mutations in DNA sequences are responsible for abnormalities in biological processes. Such mutations may be inherited by individuals from their parents by the autosomal dominant, autosomal recessive, or X-linked pattern; otherwise, they may develop *de novo* in the individual[4]. Some common rare genetic disorders include cystic fibrosis, Duchenne muscular dystrophy, Huntington's disease, sickle cell anemia, and lysosomal storage disorders. Severity and symptoms vary from mildness of borderline abnormalities to life-threatening systemic dysfunctions. One of the major difficulties in the way of rare genetic diseases is their heterogeneity. Unlike common diseases, which have well-established protocols for diagnosis and treatment, rare diseases are often undiagnosed or misdiagnosed for several years because of their rarity and their clinical symptoms that overlap. Therefore, lack of awareness and limited availability of specialized diagnostic tools pose an extra challenge to their identification[4, 5].

The field of medical genetics has made great strides in the diagnosis of rare diseases. Conventional methods of diagnosis, such as biochemical assays or histopathological examinations, are often incapable of identifying the specific genetic cause of disorders. The advent of molecular genetic methods such as whole-exome sequencing (WES) and whole-genome sequencing (WGS) took a big step toward the very accurate identification of disease-causing mutations, thereby changing the diagnostic landscape[6]. The new NGS tools are groundbreaking in the area of the diagnosis of rare diseases. They make it possible to sequence the entire genomes of individuals in less

time and with less money than could previously be done. Such new technology has proven particularly helpful to undiagnosed patients in discovering new mutations and finding out genotype-phenotype correlations. Targeted gene panels provide a more concentrated and efficient diagnostic approach when there is a suspicion of a specific disease or a group of disorders. These panels screen for the known mutations in a pre-defined set of genes associated with a disorder and, thus, provide results in a much shorter time than WES or WGS[7]. Many rare diseases are associated with chromosomal aberrations, such as deletion, duplication, or translocation, chromosomal microarray analysis (CMA) is the most powerful method for the detection of these structural variations, especially for people implying developmental delay, intellectual disability, or congenital anomalies. On the other hand, DNA sequencing provides information on variation, while RNA sequencing is the way to understand how the variation affects gene expression. The functional genomics studies, including transcriptomic and proteomic studies, give a broader look into the disease mechanism, in the direction of a personalized treatment regimen[8].

With the growing understanding of the genetic basis of rare diseases, researchers have developed innovative therapeutic strategies to correct underlying genetic defects. Such developments have opened new avenues in precision medicine to offer hope to patients who had little else available to them. Gene therapy entails the insertion, removal, or alteration of genetic material in a patient with therapeutic or preventive intent[9]. Technologies such as CRISPR-Cas9 and viral vector-mediated transfer hold great promise for the repair of mutations causing diseases. For example, gene therapy has been accomplished in the treatment of spinal muscular atrophy (SMA) and some inherited retinal diseases, oligonucleotides (ASOs) and small interfering RNAs (siRNAs), which target RNA, have become therapeutic strategies for treating genetic disorders. The therapeutic principle of antisense oligonucleotides and small interfering RNAs is to knock down mutant gene expression or upregulate a functional gene to express the gene product in desirable amounts[10]. The approval of drugs such as Spinraza (for SMA) and Tegsedi (for hereditary

transthyretin amyloidosis) indicates the success of this approach.

Most of these uncommon diseases, especially lysosomal storage disorders, are due to enzyme deficiencies. Enzyme replacement therapy is the administration of synthetic enzymes compensating for those missing or defective enzymes. It is widely adopted for Gaucher disease, Fabry disease, and Pompe disease, among other conditions, small molecules with targets for unique diseased pathways have emerged as a potential treatment option for genetic disorders[9]. These small molecules can either activate or inhibit events involving specific proteins in the disease mechanism. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, for example, have greatly improved outcomes in patients suffering from cystic fibrosis. There are stem cell-based approaches to regenerate damaged tissues and organs in the cases of genetic disorders. Such has been the case of hematopoietic stem cell transplantation (HSCT) successfully in inherited blood disorders such as sickle cell anemia and certain immunodeficiencies[11]. Nevertheless, a great deal of advancement in genetic medicine has done very little to address the dire challenges experienced in various aspects of diagnosis and treatment of some rare heritable diseases. High costs of genetic testing and therapy have become the barriers and made these tests and therapies even beyond the reach of most patients, particularly those in resource-poor countries. Besides, ethical issues regarding gene editing technologies such as CRISPR also need critical reflection to avoid any possible exploitation[8]. Another impediment is the limited knowledge about the genetic basis of many rare diseases. Even though sequencing technologies have enabled the detection of disease-causing mutations, the functional importance of many genetic variants is

still poorly defined. More work must be done to clarify gene-disease relationships and to aim towards the development of targeted therapies. Rare disease research relies on the merger of multi-omics approaches, AI-analyzed data, and patient-centric initiatives. Cooperation among researchers, clinicians, the pharmaceutical industry, and patient advocacy groups will be crucial in moving knowledge and management of these conditions forward[10].

The genetic basis of rare diseases is an area of great scientific interest owing to advancements in molecular genetics and precision medicine. The development of newer tools for diagnosis has tightened the net for these disorders, Therapeutic strategies continued to inspire hope among the affected. Although challenges exist, research and technological developments will empower us to envisage better diagnostic and therapeutic paradigms for rare genetic diseases, consequently improving their outcomes and quality of life.

Methodology

Sample Collection and DNA Extraction

Samples from patients were taken from those clinically diagnosed with rare genetic diseases. Blood, buccal swabs, and tissue biopsies were taken specifically depending on the genetic condition under study. For all participants from whom samples were obtained, informed consent was obtained, adhering to national and international ethical guidelines. Genomic DNA was extracted using a standard phenol-chloroform method or a commercial DNA extraction kit (e.g., Qiagen DNeasy Blood & Tissue Kit) to ensure high-quality DNA yield. The Nanodrop spectrophotometer was used to quantify the extracted DNA and the A260/A280 ratio was used to assess the purity. Further confirmation of DNA integrity was carried out through agarose gel electrophoresis[12].

Method	Purpose	Procedure	Outcome
DNA & RNA Extraction	Isolate high-quality nucleic acids	Blood/tissue samples are processed using kits	Pure DNA/RNA for genetic analysis
PCR & Sanger Sequencing	Detect specific mutations	PCR amplification followed by Sanger sequencing	Identification of SNPs and small mutations

Next-Generation Sequencing (NGS)	Comprehensive mutation analysis	Whole-exome sequencing and variant annotation	Detection of novel and known pathogenic variants
Gene Expression Analysis	Assess the functional impact of mutations	qRT-PCR and Western blot for RNA/protein levels	Expression changes linked to disease phenotype
CRISPR-Cas9 Gene Editing	Validate mutation effects and correction	Gene editing in patient-derived cell lines	Restored normal gene function post-editing

Polymerase Chain Reaction (PCR) and Sanger Sequencing

Using the polymerase chain reaction (PCR) methodology, genes targeted for the selected rare diseases were amplified. Gene-specific primers were designed using Primer3 software, taking care to ensure optimum specificity and efficiency. The PCR reaction was set up in a thermal cycler under optimized conditions, which included an initial denaturation step, followed by acceptable annealing, and then extension. Amplified PCR products were cleaned off using a PCR-cleanup kit (e.g., exoSAP-IT) to remove excess primers and dNTPs[13]. Sequencing of purified PCR products was done by automated Sanger sequencing (ABI 3730XL). BioEdit or Chromas software was used to analyze the sequencing data to identify single nucleotide polymorphism (SNP) or pathogenic mutations in the target genes. The resultant sequences were subjected to alignment with the reference sequences available in the National Center for Biotechnology Information (NCBI) using the BLAST tool[14].

Next-Generation Sequencing (NGS) and Bioinformatics Analysis

Whole-exome sequencing or targeted next-generation sequencing was performed for comprehensive mutation screening. The DNA libraries were prepared using the Illumina Nextera DNA Library Prep Kit, and the quality assessment was performed using a Qubit fluorometer and an Agilent 2100 Bioanalyzer. Finally, the Illumina NovaSeq platform was used for sequencing to achieve a high sequencing depth[15]. The raw sequencing reads underwent quality control using FastQC. Trimmomatic was then employed to trim low-quality reads and adapters. Sequence alignment was performed with the Burrows-Wheeler Aligner (BWA) against the human reference genome

(GRCh38). Variant calling with the Genome Analysis Toolkit (GATK) was followed by annotation using ANNOVAR and Variant Effect Predictor (VEP). Pathogenicity predictions of the detected variants were analyzed using PolyPhen-2, SIFT, and MutationTaster. The identified variants were then cross-referenced with ClinVar, OMIM, and HGMD databases to explore their putative clinical relevance[16].

Chromosomal Microarray Analysis (CMA)

The extraction of structural variations was done by performing chromosomal microarray analysis (CMA) through the platform of Affymetrix CytoScan HD. For DNA extraction, labeling, hybridization to the microarray chip, and scanning are done to detect CNV, big deletions, or duplications related to rare diseases. Data analysis was done using ChAS software and the results were compared to the Database of Genomic Variants (DGV)[17].

RNA Extraction and Gene Expression Analysis

The extraction of total RNA from blood or tissue samples was done by using the method of TRIzol reagent. Gene expression levels would be investigated in affected individuals once the concentration and purity of RNA were quantified with a Nanodrop spectrophotometer and thereafter assayed for integrity by electrophoresis on an agarose gel. Using a high-capacity cDNA reverse transcription kit, complementary DNA (cDNA) synthesis was carried out.

Quantitative real-time PCR (qRT-PCR) analysis was performed using SYBR Green chemistry on a QuantStudio 5 Real-Time PCR System. Internal controls include housekeeping genes like GAPDH and β -actin. Relative gene expression levels were calculated according to the $2^{-\Delta\Delta Ct}$ method[18].

Protein Expression and Functional Analysis

Western blot analysis was performed to substantiate the effect of genetic mutations on proteins. Protein lysates from patient-derived cells were quantified using the Bradford assay. SDS-PAGE and transfer onto a PVDF membrane were performed. The membranes were treated with primary antibodies against the target protein followed by incubation using HRP-conjugated secondary antibodies. The protein bands were visualized using an enhanced chemiluminescence (ECL) detection system. Densitometric analysis was performed using ImageJ software[19].

CRISPR-Cas9 Gene Editing for Functional Validation

To establish pathogenicity for the identified genetic variants, CRISPR-Cas9-mediated editing was performed in human cell lines. Single guide RNAs (sgRNAs) were designed using CRISPR design tools and cloned into a CRISPR-Cas9 expression vector. The vectors were transfected into HEK293T cells via Lipofectamine 3000. DNA extraction was done after transfection, and gene-editing efficiencies were determined with the T7E1 mismatch detection assay and Sanger sequencing. Functional assays were performed to determine the phenotypic effects of gene correction[20].

Statistical Analysis

All the experimental data were analyzed using GraphPad Prism. Statistical significance was determined by the Student's t-test or ANOVA where applicable. The data are presented as mean \pm standard

deviation (SD), with p-values < 0.05 considered statistically significant. This approach employs molecular biology techniques, bioinformatic tools, and functional assays for a complete analysis of the genetic basis of rare diseases for diagnosis and therapy improvement[21].

Results

DNA Extraction and Quality Assessment


Genomic DNA isolates were successfully obtained from all samples collected from the patients using peripheral blood, buccal swabs, and tissue biopsies. The same might be assessed using the A260/A280 ratio that gave values of 1.8-2.0, indicating that the extracts could be classified as good for downstream applications. Further confirmation of the quality was through agarose gel electrophoresis, showing quite distinct high molecular weight bands in all samples examined, confirming minor degradation.

PCR Amplification and Sanger Sequencing

Indeed, the successful PCR amplification of target genes implicated in rare diseases was corroborated by the presence of a clear and specific amplicon on agarose gel electrophoresis. The Sanger-sequenced amplicons revealed multiple SNPs and point mutations in the target genes. Upon alignment of the obtained sequences with reference genomes, several pathogenic mutations in the form of missense, nonsense, and frameshift were detected. The mutations obtained were compared to those in the ClinVar and HGMD databases that were already known to cause disease, which were found to support the pathogenicity.

Next-Generation Sequencing and Variant Analysis

Whole Exon Sequencing (WES) and Targeted-Next Generation Sequencing (NGS) provide high-quality reads



With an average sequencing depth of 100×. Quality control and data filtering yielded, on average, 85 million high-quality reads per sample. Variant calling then identified several previously known pathogenic mutations along with several novel genetic variants of uncertain significance being annotated by ANNOVAR and VEP, 40% of the variants were classified as benign, 35% as likely pathogenic, and 25% as pathogenic. Pathogenic variants were further functionally assessed by computational predictions such as PolyPhen-2 and SIFT. Several structural variants were identified, including large deletions and duplications, some of which were known to be associated with syndromic disorders.

Chromosomal Microarray Analysis (CMA)

Chromosomal microarray analysis was able to successfully identify copy number variations (CNVs) in some patient samples. Deletion and duplication events were determined in chromosomal regions related to genetic syndromes. The CNVs were cross-referenced with the Database of Genomic Variants (DGV) and in several instances found to be confirmed disease-associated. Some unique chromosomal rearrangements were found for some patients and merit further investigation.

Gene Expression Analysis

The extraction of RNA proved to be very fruitful, and with high RNA integrity numbers (RIN > 7) assigned to the samples, it was established that the RNA underwent minimal degradation. qRT-PCR analysis revealed that gene expression levels varied significantly from healthy control in the patients. Apart from this, several genes associated with the disease have been shown to have their expression increased or decreased, thus proving their role in the development of the studied rare conditions. The changes in expression matched specific mutations discovered through genetic analysis, thus adding to establishing their functional relevance.

Protein Expression and Western Blot Analysis

Changes to protein expression were found to be altered in these patients, as evidenced by Western blot analysis. Somatic loss-of-function mutations in cases indicated decreased expression of key proteins, whereas gain-of-function mutations enhanced

expression. Densitometric analysis showed statistically significant differences in protein levels compared with healthy controls ($p < 0.05$), implicating these mutations in disease pathogenesis.

CRISPR-Cas9 Gene Editing and Functional Validation

In the gene correction performed on Cas9-edited cell lines, normal gene functioning was restored. The gene editing was perceived to be quite efficient with the T7E1 mismatch detection assay, with the rate of correction exceeding 60%. Functional assays revealed improved post-editing cellular phenotypes, including the normalization of gene expression and restoration of protein function. This finding very strongly supports the argument that the mutations identified are responsible for the disease phenotypes seen in patients.

Statistical Analysis

All statistical tests confirmed the significance of the changes in question concerning the genotype and functional assays carried out. Student's t-test and ANOVA gave p-values of less than 0.05 for the gene and protein quantification tests, thus validating the credibility of the results. Statistically significant correlations between genetic mutations, gene expression, and protein abnormalities proved the relevance of these genetic variants in rare disease pathology. It provides a consolidated sentiment on a comprehensive genetic and molecular character of rare diseases, which offers an acquired golden opportunity for identification and potential treatments.

Discussion

This research has huge implications for understanding the underlying genetic cause of rare diseases, underlining the role of modern molecular techniques in accurate diagnosis and timely therapeutic intervention. PCR-based mutation screening, next-generation sequencing (NGS), chromosomal microarray analysis (CMA), gene expression profiling, and functional validation using CRISPR-Cas9 together serve to present a full logistic framework for detecting mutations associated with diseases and their biological consequences.[22].

Reliable downstream analyses necessitated the successful extraction of highly purified genomic DNA and RNA from patient samples. Nucleic acid purity and integrity were confirmed first through the A260/A280 ratio and subsequently by gel electrophoresis, which ensured further accurate results in PCR amplification, sequencing, and expression analysis premise of PCR-Sanger sequencing for identifying several pathogenic single-nucleotide polymorphisms (SNPs) and mutations in disease-associated genes laid the groundwork for using this approach in targeted genetic screening[23]. However, Sanger sequencing also has its limitations. Larger deletions or complex structural variants cannot be detected very well with Sanger, hence combining NGS and CMA would provide comprehensive genetic profiling.

As far as methods of high-throughput have been known, one method relates to identifying new and known mutations associated with rare diseases through NGS-based whole-exome sequencing (WES). The depth of sequencing reached high confidence for variant calling, indicating a considerable proportion of most probably pathogenic and pathogenic variants, many of which have already been reported in ClinVar and HGMD, proving their relevance to the disease[24]. Nonetheless, one-fourth of the proposed variants were indistinctly termed variants of uncertain significance; hence, further functional studies to ascertain their pathogenicity are warranted. The large deletions and duplications identified form a major structural variation and are therefore considered another advantage of NGS over conventional sequencing methods.

Especially in patients who present with syndromes, CMA plays an important role in identifying CNVs. Detection of large chromosomal deletions and duplications in suspected regions of a disease is consistent with other studies linking CNVs to various genetic disorders, verifying these findings with the Database of Genomic Variants (DGV), further clinical interpretation of these structural abnormalities was made[25]. On the other hand, CMA cannot detect balanced chromosomal rearrangement or single-nucleotide mutation cases; thus emphasizing the complementary nature of various approaches to genetic screening. Gene

expression analysis gave quite useful insights toward understanding the functional impact of mutations. Upregulation or downregulation of gene expression in patient samples of certain key disease-associated genes is evidence confirming the involvement of these genetic alterations in disease pathogenesis[26]. The expression changes we noted were consistent with other mechanisms reported for similar disorders, which argue that these mutations were therefore capable of affecting biological pathways inappropriately. Thus, mutations are correlated with expression changes, which only increases the relevance of transcriptomic analysis in discerning disease mechanisms that go beyond simple DNA-level changes.

Functional impact validation by protein expression profiling further supports impacts created by genetic mutations at the translational level. Western blot analysis shows a strong relation between pathogenic variants and changed protein expression. Loss-of-function mutations reduced protein amounts, while gain mutations caused aberrant overexpression[27]. These data further reinforce the concept that genetic alterations can occur at multiple molecular levels-from transcription to translation. Statistically significant differences in protein expression between the patient and control gave important evidence for the pathogenicity of the identified mutations.

The efficiency of CRISPR-Cas9 editing was impressively high, thus demonstrating the possibility of this technology acting as a therapeutic tool to genetically correct an individual. These findings corroborate the emerging studies that delve into CRISPR-based therapeutics for genetic disorders for use in precision medicine[28]. Although this study does provide a strong genetic and molecular characterization of rare diseases, certain limitations must be stated. The sample size was relatively small, which might limit the generalizability of the findings. Other studies in vivo will indicate more meaningful effects these mutations have on organismal systems. While pathogenicity was consolidated for some of these mutations through in vitro functional assays, several variants of interest were classified as VUS such that they were not clear in their interpretation of genetic data and would require larger population studies as well as functional validation[29].

There are limitations to this research, but it plays a vital role in understanding rare diseases through integrated multi-molecular approaches. The results corroborate the use of genome-wide genetic screening for early diagnosis and a subsequent personalization of treatment strategies. Future investigations will involve larger patient cohorts evaluated by multi-omics and with new health interventions including gene therapy and targeted drug development. Indeed, this study appears aptly to illustrate how rare genetic afflictions may dissolve from the molecular genetics perspective. High-throughput sequencing complemented with expression analysis and clinics gives the full spectrum of disease mechanisms and helps in reaching a paradigm. These findings refine the definition and improve the process of diagnosis, promising even the possibility of developing therapeutic measures to restore hope for patients suffering from very rare genetic disorders.

Conclusion

The main findings of this study demonstrate that molecular genetic methods are very important in the diagnosis and understanding of rare diseases. We identified the pathogenic mutations by employing PCR, next-generation sequencing, chromosomal microarray analysis, gene expression profiling, and CRISPR-Cas9 gene editing and evaluated their functional consequences. This shows the evidence of their general importance in extensive molecular analysis, i.e., genetic alterations, aberrant expression of specific genes, and abnormal levels of proteins. Functional validation through gene editing also reveals the definitive causal link from mutations to the affected disease phenotypes, changes may assist in advancing precision medicine in the face of variant

interpretation difficulties, but more studies are needed to increase the sample size and broaden the scope of research in gene-targeted therapy. This study consolidates gene screening and molecular diagnostics in the direction of early diagnosis and treatment planning in rare diseases.

Acknowledgment:

We highly acknowledge The Islamia University of Bahawalpur, which provided us with the platform, labs, and internet source to search for the article.

Author contribution:

The authors confirm their contribution to the paper as follows: study conception, Dr Muhammad Amjad Chisti and Design by Maryam Jan, Data Collection, Analysis, and interpretation of results, Imran Hussain, and Draft and manuscript preparation by Abdul Basit and Atif Rasool. All authors reviewed the results and approved the final version of the manuscript.

Data Availability:

All the work is performed in the labs of the Islamia University of Bahawalpur and the Haripur University COMSATS University Islamabad Lahore Campus and supporting data is collected from different authentic research papers.

Funding:

No funding was granted from any source.

Conflicts of interest:

The authors declare no conflict of interest.

REFERENCES

1. Richter, T., et al., *Rare disease terminology and definitions—a systematic global review: report of the ISPOR rare disease special interest group*. Value in health, 2015. 18(6): p. 906-914.
2. Nguengang Wakap, S., et al., *Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database*. European journal of human genetics, 2020. 28(2): p. 165-173.
3. Stoller, J.K., *The challenge of rare diseases*. Chest, 2018. 153(6): p. 1309-1314.
4. Stranneheim, H. and A. Wedell, *Exome and genome sequencing: a revolution for the discovery and diagnosis of monogenic disorders*. Journal of Internal Medicine, 2016. 279(1): p. 3-15.
5. Pogue, R.E., et al., *Rare genetic diseases: update on diagnosis, treatment, and online resources*. Drug discovery today, 2018. 23(1): p. 187-195.

6. Banoon, S.R., T.S. Salih, and A. Ghasemian, *Genetic mutations, and major human disorders: A review*. Egyptian Journal of Chemistry, 2022. **65**(2): p. 571-589.
7. Wright, C.F., D.R. FitzPatrick, and H.V. Firth, *Paediatric genomics: diagnosing rare disease in children*. Nature Reviews Genetics, 2018. **19**(5): p. 253-268.
8. Fernandez-Marmiesse, A., S. Gouveia, and M.L. Couce, *NGS technologies as a turning point in rare disease research, diagnosis, and treatment*. Current medicinal chemistry, 2018. **25**(3): p. 404-432.
9. Marwaha, S., J.W. Knowles, and E.A. Ashley, *A guide for the diagnosis of rare and undiagnosed disease: beyond the exome*. Genome medicine, 2022. **14**(1): p. 23.
10. Alsaidan, O.A., *Nanocarriers: Exploring the potential of oligonucleotide delivery*. Current Drug Delivery, 2025.
11. Hartley, T., et al., *New diagnostic approaches for undiagnosed rare genetic diseases*. Annual review of genomics and human genetics, 2020. **21**(1): p. 351-372.
12. Deviaene, M., et al., *Sample adequacy controls for infectious disease diagnosis by oral swabbing*. PLOS One, 2020. **15**(10): p. e0241542.
13. Wood, S.A., et al., *A comparison of droplet digital polymerase chain reaction (PCR), quantitative PCR, and metabarcoding for species-specific detection in environmental DNA*. Molecular Ecology Resources, 2019. **19**(6): p. 1407-1419.
14. Green, S.J., R. Venkatramanan, and A. Naqib, *Deconstructing the polymerase chain reaction: understanding and correcting bias associated with primer degeneracies and primer-template mismatches*. PloS One, 2015. **10**(5): p. e0128122.
15. Zhao, S., et al., *All-in-one sequencing: An improved library preparation method for cost-effective and high-throughput next-generation sequencing*. Plant Methods, 2020. **16**: p. 1-14.
16. Fang, B., et al., *Genetic characterization of human adenoviruses in patients using metagenomic next-generation sequencing in Hubei, China, from 2018 to 2019*. Frontiers in Microbiology, 2023. **14**: p. 1153728.
17. Xia, M., et al., *Application of chromosome microarray analysis in prenatal diagnosis*. BMC pregnancy and childbirth, 2020. **20**: p. 1-11.
18. Wai, H.A., et al., *Short amplicon reverse transcription-polymerase chain reaction detects aberrant splicing in genes with low expression in blood missed by ribonucleic acid sequencing analysis for clinical diagnosis*. Human Mutation, 2022. **43**(7): p. 963-970.
19. Gorr, T.A. and J. Vogel, *Western blotting revisited: critical perusal of underappreciated technical issues*. PROTEOMICS-Clinical Applications, 2015. **9**(3-4): p. 396-405.
20. Ma, N., et al., *Determining the pathogenicity of a genomic variant of uncertain significance using CRISPR/Cas9 and human-induced pluripotent stem cells*. Circulation, 2018. **138**(23): p. 2666-2681.
21. Benakanakere, M.R., et al., *Investigation of the functional role of human Interleukin-8 gene haplotypes by CRISPR/Cas9 mediated genome editing*. Scientific Reports, 2016. **6**(1): p. 31180.
22. Mujica, E., *Functional characterization of candidate genes for cardiometabolic diseases: A CRISPR/Cas9 and in vivo image-based approach*. 2024, Acta Universitatis Upsaliensis.
23. Cohen, S., et al., *A tool for CRISPR-Cas9 sgRNA evaluation based on computational models of gene expression*. Genome Medicine, 2024. **16**(1): p. 152.
24. Sherkatghanad, Z., et al., *Using traditional machine learning and deep learning methods for on-and off-target prediction in CRISPR/Cas9: a review*. Briefings in Bioinformatics, 2023. **24**(3): p. bbad131.
25. Capkova, P., et al., *MLPA is a practical and complementary alternative to CMA for diagnostic testing in patients with autism spectrum disorders and identifying new candidate CNVs associated with autism*. PeerJ, 2019. **6**: p. e6183.
26. Rosenfeld, J.A. and A. Patel, *Chromosomal microarrays: understanding genetics of neurodevelopmental disorders and congenital anomalies*. Journal of Pediatric Genetics, 2017. **6**(01): p. 042-050.

27. Alvarez, M.J., et al., *Functional characterization of somatic mutations in cancer using network-based inference of protein activity*. Nature Genetics, 2016. 48(8): p. 838-847.
28. Li, X., et al., *The impact of rare variation on gene expression across tissues*. Nature, 2017. 550(7675): p. 239-243.
29. Yazar, M., *Computational Investigation of Structural and Functional Effects of Cancer Related Variants*. 2023, Marmara Universitesi (Turkey).

